No Data
WuXi XDC Announces Leadership and Committee Roles
Wuxi xdc (02268.HK): Kenneth Walton Hitchner III has been appointed as an independent non-executive director.
Gelonghui November 21st, Wuxi XDC (02268.HK) announced that Stewart John Hen has resigned as an independent non-executive director as well as a member of the board of directors' audit committee, remuneration committee, and global strategy committee (collectively referred to as "such committees"), effective from November 21, 2024, in order to devote more time to his other personal commitments. The board of directors also gladly announced that Kenneth Walton Hitchner III has been appointed as an independent non-executive director, effective from November 21, 2024.
Open Source Securities' investment strategy for the pharmaceutical industry in 2025: The long-term industry trend has not changed, focusing on the sector stabilizing and rebounding.
At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, and the continuous improvement of enterprise innovation capabilities are long-term industry trends that have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance income suppressing the pharmaceutical sector will gradually improve.
Hong Kong stock market anomaly | CRO concept stocks have a leading increase, institutions believe that the future performance recovery is worth looking forward to. The demand for cost reduction in research and development of innovative drugs listed in the
CRO concept stocks are among the top gainers. As of the time of publication, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.
[Brokerage Focus] Bocom Intl believes that the prospects of domestic CXO overseas business are mixed after Trump's election.
Golden Harvest Financial News | Bocom Intl research reports indicate that the prospects for domestic CXO overseas business after Trump's election are both positive and negative: 1) A Republican-controlled Congress may advocate 'America first' in the pharmaceutical supply chain; 2) The IRA signed by the Biden administration has an uncertain future under the Trump administration; 3) Trump may give more management responsibilities to Robert Kennedy Jr. in the medical health field, who opposes vaccines and claims to make significant reforms to the American medical healthcare system, which may bring certain pressure to downstream customers of CXO; 4) Trump's tariff policy and overall loose fiscal policy stance could lead to subsequent inflation.
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}